Pharma and a few penny stocks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS TRUMPS ALL. NEWS DROPPING TOMORROW
NEWS
KALY Confirms Pharmaceutical Cannabis Extract Report On Recent Trials Scheduled For Tomorrow
1:18 pm ET March 21, 2019 (Globe Newswire) Print
-- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
EXPLODING UP TO .02 and BEYOND
Yeah this is going to do very well. I have been sitting on shares for months.. I was a very active posted but left for a break. Lots of great DD months ago. This is trending upward in the days to come.
Yeah I have been in for months but went silent for awhile as I took an extended vacation during Christmas. Nice to see a rise here. I am expecting .01 but Summer if not sooner. Slow and steady
My .0025s from months ago are safe and locked away for a long time. 2020 or bust. LOL
ASK BUILDING AGAIN
we may have to wait awhile for that pps but it is trending way up from last week.
This trades so well. Got more at 1.80 yesterday and sold at $2 then reloaded on the dip. Love this stock
I was going to wait for the penny break to celebrate but we are almost there. I took an extended break for the holidays and then decided to just relax a couple more months. I think we will be back above a penny fairly soon and then it will get interesting again. I hope every has been well and has been having a fruitful 2019. DD express will be getting back on track soon. All the best.. BH
DARE JUST POPPED HARD>>> BULLS COMING IN
HUGE BID SUPPORT at $1.73
This is why you get in when it is still quiet :) I have been in since last week below $1. :)
Looking good again today. Hope to see a pop during that 12:30pm presentation with more good news :)
HOD break coming soon IMO
Presenting again at 9:30am Pacific Time. 12:30pm Eastern Time. It could be a spicy lunch today :)
Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
PDF Version
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesdsay, March 19th, 2019 starting at 9:30 a.m. Pacific Time in Orange County, CA. Ms. Johnson will present a Daré overview and provide an update on the Company’s new late-stage bacterial vaginosis program, DARE-BV1, a proprietary solution-to-gel formulation containing clindamycin, an antibiotic used to treat bacterial infections, as well as Daré’s mid-stage programs: Ovaprene®, a potential first-in-class hormone-free contraceptive solution; and Sildenafil Cream, 3.6%, a novel vaginally delivered formulation of sildenafil, the active ingredient in Viagra®, for the potential treatment of female sexual arousal disorder (FSAD). Ms. Johnson will also review Daré’s earlier stage programs, including DARE-HRT1, a potential first combination vaginal ring that would deliver both natural estradiol and natural progesterone together over 28 days to treat vasomotor symptoms (VMS) associated with menopause as part of a hormone replacement therapy regimen.
The presentation will be webcast live and may be accessed by visiting Daré’s website at http://ir.darebioscience.com. A replay of the webcast will be available for 10 business days.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s sexual health, vaginal health, fertility, and contraception. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-class candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the active ingredient in Viagra®, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application, DARE-BV1. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré uses these channels to communicate with its investors and the public about the company and other company-related matters. The information Daré posts on its investor relations website may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Alex Gray
Burns McClellan
agray@burnsmc.com
212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
Amanda Guisbond
Canale Communications
amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience
Dare´ logo stacked.png
Source: Dare Bioscience, Inc.
Back after a long long break from IHUB. I was in DARE in the .80s and sold yesterday when it spiked. Made some nice coin. I bought back in today at $1.85
Looks like we are going to rock again. GLTA
Hemper in the HOUSEEEEEE
http://ir.darebioscience.com/
Sabrina Johnson, President and Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesdsay, March 19th, 2019 starting at 9:30 a.m. Pacific Time in Orange County, CA. Ms. Johnson will present a Daré overview and provide an update on the Company's new late-stage bacterial vaginosis program, DARE-BV1, a proprietary solution-to-gel formulation containing clindamycin, an antibiotic used to treat bacterial infections, as well as Daré's mid-stage programs: Ovaprene®, a potential first-in-class hormone-free contraceptive solution; and Sildenafil Cream, 3.6%, a novel vaginally delivered formulation of sildenafil, the active ingredient in Viagra®, for the potential treatment of female sexual arousal disorder (FSAD). Ms. Johnson will also review Daré's earlier stage programs, including DARE-HRT1, a potential first combination vaginal ring that would deliver both natural estradiol and natural progesterone together over 28 days to treat vasomotor symptoms (VMS) associated with menopause as part of a hormone replacement therapy regimen.
Great close. Been averaging down all day LOL.
Have a great weekend gang.
Go TIME
BREAK OUT!!!!!!!! I just wanted to say that... LOL. Merry Christmas.
Well we started off well anyway. Just giving it all back LOL
down almost 400 points. Broke below 23,000. We don't need a wall we need a floor. LOL.
The Dow is crashing. My money is safer here. LOL
more buying below .02 :)
Great details. Have you a follow. I like the sound of that. .003 would be amazing :)
I bought earlier in the day and say bid. Was going to slap 4 but I wanted to see if 3s would fill. Got 6 milly
i nabbed a load of 3s. I like that number LOL.
Same. Cheers
The last trip zero I was in sat .0003 for weeks and then popped to .0015. :)
The bounce off of 16 today.
I got my 3s. LET HER RIP
LOL. Love it when a bounce occurs after a shake :)
Agree
Doing some DD here. I saw the volume here and got curios
With games life Fortnite going crazy this is a great time to own shares here. As they add more influencers and platforms this will start to generate some decent revenue. Gaming is a huge industry. I am glad to be able to get some cheaper shares today. Going into 2019 with a positive outlook IMO
LOL.
I just got here recently. I havn't been pumping at all to be honest. LOL. I am doing my usual buy too high and average down routine. Then when it goes back up I sell for a profit. Have a good one. :)